Literature DB >> 5360524

Immunological relationships between hexons of certain human adenoviruses.

E Norrby, G Wadell.   

Abstract

Antisera against hexons of serotypes 2, 4, 5, and 6 (subgroup III), and 15 (subgroup II) were absorbed with purified hexons of various serotypes representing the different subgroups of human adenoviruses. Group, subgroup, and type specificities of hexons could be distinguished. The subgroup specificity of type 4 hexons resembled that of hexons of subgroup I members (types 3, 11, and 16). Antihexon sera gave a type-specific inhibition of virion-associated hemagglutinin. The inhibiting activity of different sera was found to be inversely related to the length of fibers of the serotype concerned. Virions of serotypes carrying fibers shorter than about 20 nm (types 3, 4, 9, 11, and 15) were readily inhibited, whereas those of serotypes with longer fibers (types 2 and 6) were inhibited only by relatively large amounts of antibody measured in terms of homotypic complement fixation activity. The reciprocal cross-neutralization between serotypes 4 and 16 was studied separately. Hexons of both serotypes each carried a type-specific component and, in addition, a unique antigen specificity common to the two types. This common antigen specificity was interpreted to be available to a larger extent at the surface of virions (and probably also isolated hexons) of type 4 than of type 16. These results suggest an explanation for the predominantly one-sided character of the cross-neutralization between types 4 and 16.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5360524      PMCID: PMC375923     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Electron microscopy of an antibody-hapten complex.

Authors:  R C Valentine; N M Green
Journal:  J Mol Biol       Date:  1967-08-14       Impact factor: 5.469

2.  Univalent fragments of antibody: a study by electron microscopy.

Authors:  J D Almeida; B Cinader; D Naylor
Journal:  Immunochemistry       Date:  1965-06

3.  Transformation of primary rat embryo cells by adenovirus type 2.

Authors:  A E Freeman; P H Black; E A Vanderpool; P H Henry; J B Austin; R J Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  1967-09       Impact factor: 11.205

4.  The relationship between soluble antigens and the virion of adenovirus type 3. 3. Immunological identification of fiber antigen and isolated vertex capsomer antigen.

Authors:  E Norrby; P Skaaret
Journal:  Virology       Date:  1967-07       Impact factor: 3.616

5.  Identification of soluble components of adenovirus type 11.

Authors:  E Norrby
Journal:  J Gen Virol       Date:  1968-01       Impact factor: 3.891

6.  Biochemical studies on adenovirus multiplication. IX. Chemical and base composition analysis of 28 human adenoviruses.

Authors:  M Piña; M Green
Journal:  Proc Natl Acad Sci U S A       Date:  1965-08       Impact factor: 11.205

7.  Standardization and certification of reference antigens and antisera for 30 human adenovirus serotypes.

Authors:  D A Stevens; M Schaeffer; J P Fox; C D Brandt; M Romano
Journal:  Am J Epidemiol       Date:  1967-11       Impact factor: 4.897

8.  The relationship between the soluble antigens and the virion of adenovirus type 3. I. Morphological characteristics.

Authors:  E Norrby
Journal:  Virology       Date:  1966-02       Impact factor: 3.616

9.  The relationship between the soluble antigens and the virion of adenovirus type 3. II. Identification and characterization of an incomplete hemagglutinin.

Authors:  E Norrby
Journal:  Virology       Date:  1966-12       Impact factor: 3.616

10.  The mechanism of viral carcinogenesis by DNA mammalian viruses: DNA-DNA homology relationships among the "weakly" oncogenic human adenoviruses.

Authors:  S La; M Green
Journal:  J Gen Virol       Date:  1967-10       Impact factor: 3.891

View more
  18 in total

1.  Preparation and evaluation of chicken embryo-adapted fowl adenovirus serotype 4 vaccine in broiler chickens.

Authors:  Muhammad Khalid Mansoor; Iftikhar Hussain; Muhammad Arshad; Ghulam Muhammad
Journal:  Trop Anim Health Prod       Date:  2010-09-28       Impact factor: 1.559

2.  Grouping of monoclonal antibodies to adenovirus hexons by their cross-reactivity.

Authors:  E Adám; A Lengyel; M Takács; J Erdei; J Fachet; I Nász
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

3.  Sequence of the avian adenovirus FAV 1 (CELO) DNA encoding the hexon-associated protein pVI and hexon.

Authors:  T A Akopian; K K Doronin; V A Karpov; B S Naroditsky
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

4.  Comparison of neutralization and DNA restriction enzyme methods for typing clinical isolates of human adenovirus.

Authors:  K H Fife; R Ashley; A F Shields; D Salter; J D Meyers; L Corey
Journal:  J Clin Microbiol       Date:  1985-07       Impact factor: 5.948

5.  Characterization of group II avian adenoviruses with a panel of monoclonal antibodies.

Authors:  J V van den Hurk; S van Drunen Littel-van den Hurk
Journal:  Can J Vet Res       Date:  1988-10       Impact factor: 1.310

6.  [Successive multiple immunization with adenoviruses].

Authors:  R Wigand; J T Kho
Journal:  Z Med Mikrobiol Immunol       Date:  1970

7.  Capsid mosaics of intermediate strains of human adenoviruses.

Authors:  E Norrby
Journal:  J Virol       Date:  1969-11       Impact factor: 5.103

8.  Preparation and characterization of monoclonal antibodies to enteric adenovirus types 40 and 41.

Authors:  J E Herrmann; D M Perron-Henry; D Stobbs-Walro; N R Blacklow
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

9.  Comparative sequence analysis of the inverted terminal repetitions from different adenoviruses.

Authors:  M Shinagawa; R Padmanabhan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

10.  Immunological and other biological characteristics of pentons of human adenoviruses.

Authors:  G Wadell; E Norrby
Journal:  J Virol       Date:  1969-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.